

**28 July 2017**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai - 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Respected Sir / Madam,

**Subject: Outcome of Board Meeting held today and Submission of Unaudited Standalone Financial Results for the quarter ended on 30 June 2017**

**Start Time: 9.45 am**

**Conclusion Time: 10.10 am**

This is in reference to our letter dated 20 July 2017 intimating the date of the Board Meeting for consideration of the Unaudited Standalone Financial Results for the quarter ended on 30 June 2017.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the Unaudited Standalone Financial Results for the quarter ended on 30 June 2017.

We attach herewith:

- 1) The approved Unaudited Standalone Financial Results under Regulations 33 of SEBI (LODR) Regulations, 2015 and Limited Review Report from Auditors.
- 2) Press Release issued in this regard

We would like to inform you that, the Board of Directors in their meeting held today, have decided and approved to make an investment in its wholly owned subsidiary Company namely Hester Biosciences Kenya Limited, incorporated in the Kenya, Africa, to the extent of USD 150,000 (US Dollar One Lakh Fifty Thousand Only). The details of Hester Biosciences Kenya Limited are given in the attached annexure.

We are arranging to publish these results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

**Sincerely,  
For Hester Biosciences Limited**



**Rajiv Gandhi**  
**CEO & Managing Director**  
**DIN: 00438037**